1
|
Fletcher D, Brown E, Javadala J, Uysal‐Onganer P, Guinn B. microRNA expression in acute myeloid leukaemia: New targets for therapy? EJHAEM 2022; 3:596-608. [PMID: 36051053 PMCID: PMC9421970 DOI: 10.1002/jha2.441] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 03/27/2022] [Accepted: 03/31/2022] [Indexed: 11/09/2022]
Abstract
Recent studies have shown that short non-coding RNAs, known as microRNAs (miRNAs) and their dysregulation, are implicated in the pathogenesis of acute myeloid leukaemia (AML). This is due to their role in the control of gene expression in a variety of molecular pathways. Therapies involving miRNA suppression and replacement have been developed. The normalisation of expression and the subsequent impact on AML cells have been investigated for some miRNAs, demonstrating their potential to act as therapeutic targets. Focussing on miRs with therapeutic potential, we have reviewed those that have a significant impact on the aberrant biological processes associated with AML, and crucially, impact leukaemic stem cell survival. We describe six miRNAs in preclinical trials (miR-21, miR-29b, miR-126, miR-181a, miR-223 and miR-196b) and two miRNAs that are in clinical trials (miR-29 and miR-155). However none have been used to treat AML patients and greater efforts are needed to develop miRNA therapies that could benefit AML patients in the future.
Collapse
Affiliation(s)
| | - Elliott Brown
- Department of Biomedical SciencesUniversity of HullHull, UK
| | | | - Pinar Uysal‐Onganer
- Cancer Research GroupSchool of Life SciencesUniversity of WestminsterLondonUK
| | | |
Collapse
|
2
|
Stavast CJ, van Zuijen I, Karkoulia E, Özçelik A, van Hoven-Beijen A, Leon LG, Voerman JSA, Janssen GMC, van Veelen PA, Burocziova M, Brouwer RWW, van IJcken WFJ, Maas A, Bindels EM, van der Velden VHJ, Schliehe C, Katsikis PD, Alberich-Jorda M, Erkeland SJ. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia 2022; 36:687-700. [PMID: 34741119 PMCID: PMC8885418 DOI: 10.1038/s41375-021-01461-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 10/18/2021] [Accepted: 10/20/2021] [Indexed: 12/03/2022]
Abstract
MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show that MLL-AF9 expression in hematopoietic precursors caused epigenetic silencing of MIR139, whereas overexpression of MIR139 inhibited in vitro and in vivo AML outgrowth. We identified novel miR-139 targets that mediate the tumor-suppressing activities of miR-139 in MLL-AF9 AML. We revealed that two enhancer regions control MIR139 expression and found that the polycomb repressive complex 2 (PRC2) downstream of MLL-AF9 epigenetically silenced MIR139 in AML. Finally, a genome-wide CRISPR-Cas9 knockout screen revealed RNA Polymerase 2 Subunit M (POLR2M) as a novel MIR139-regulatory factor. Our findings elucidate the molecular control of tumor suppressor MIR139 and reveal a role for POLR2M in the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML. In addition, we confirmed these findings in human AML cell lines with different oncogenic aberrations, suggesting that this is a more common oncogenic mechanism in AML. Our results may pave the way for new targeted therapy in AML.
Collapse
Affiliation(s)
- Christiaan J Stavast
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - Iris van Zuijen
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - Elena Karkoulia
- Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
- Childhood Leukemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Arman Özçelik
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | | | - Leticia G Leon
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - Jane S A Voerman
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - George M C Janssen
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands
| | - Peter A van Veelen
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands
| | - Monika Burocziova
- Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
| | - Rutger W W Brouwer
- Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands
- Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands
| | - Wilfred F J van IJcken
- Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands
- Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands
| | - Alex Maas
- Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands
| | - Eric M Bindels
- Erasmus MC, University Medical Center Rotterdam, Department of Hematology, Rotterdam, the Netherlands
| | | | - Christopher Schliehe
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - Peter D Katsikis
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
| | - Meritxell Alberich-Jorda
- Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
- Childhood Leukemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Stefan J Erkeland
- Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands.
| |
Collapse
|
3
|
Stavast CJ, van Zuijen I, Erkeland SJ. MicroRNA-139, an Emerging Gate-Keeper in Various Types of Cancer. Cells 2022; 11:cells11050769. [PMID: 35269391 PMCID: PMC8909004 DOI: 10.3390/cells11050769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 02/17/2022] [Accepted: 02/19/2022] [Indexed: 11/25/2022] Open
Abstract
Mounting data show that MIR139 is commonly silenced in solid cancer and hematological malignancies. MIR139 acts as a critical tumor suppressor by tuning the cellular response to different types of stress, including DNA damage, and by repressing oncogenic signaling pathways. Recently, novel insights into the mechanism of MIR139 silencing in tumor cells have been described. These include epigenetic silencing, inhibition of POL-II transcriptional activity on gene regulatory elements, enhanced expression of competing RNAs and post-transcriptional regulation by the microprocessor complex. Some of these MIR139-silencing mechanisms have been demonstrated in different types of cancer, suggesting that these are more general oncogenic events. Reactivation of MIR139 expression in tumor cells causes inhibition of tumor cell expansion and induction of cell death by the repression of oncogenic mRNA targets. In this review, we discuss the different aspects of MIR139 as a tumor suppressor gene and give an overview on different transcriptional mechanisms regulating MIR139 in oncogenic stress and across different types of cancer. The novel insights into the expression regulation and the tumor-suppressing activities of MIR139 may pave the way to new treatment options for cancer.
Collapse
|
4
|
Hope JL, Zhao M, Stairiker CJ, Kiernan CH, Carey AJ, Mueller YM, van Meurs M, Brouwers-Haspels I, Otero DC, Bae EA, Faso HA, Maas A, de Looper H, Fortina PM, Rigoutsos I, Bradley LM, Erkeland SJ, Katsikis PD. MicroRNA-139 Expression Is Dispensable for the Generation of Influenza-Specific CD8 + T Cell Responses. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2022; 208:603-617. [PMID: 35022277 PMCID: PMC10118001 DOI: 10.4049/jimmunol.2000621] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 11/15/2021] [Indexed: 01/09/2023]
Abstract
MicroRNAs (miRNAs/miRs) are small, endogenous noncoding RNAs that are important post-transcriptional regulators with clear roles in the development of the immune system and immune responses. Using miRNA microarray profiling, we characterized the expression profile of naive and in vivo generated murine effector antiviral CD8+ T cells. We observed that out of 362 measurable mature miRNAs, 120 were differentially expressed by at least 2-fold in influenza-specific effector CD8+ CTLs compared with naive CD8+ T cells. One miRNA found to be highly downregulated on both strands in effector CTLs was miR-139. Because previous studies have indicated a role for miR-139-mediated regulation of CTL effector responses, we hypothesized that deletion of miR-139 would enhance antiviral CTL responses during influenza virus infection. We generated miR-139-/- mice or overexpressed miR-139 in T cells to assess the functional contribution of miR-139 expression in CD8+ T cell responses. Our study demonstrates that the development of naive T cells and generation or differentiation of effector or memory CD8+ T cell responses to influenza virus infection are not impacted by miR-139 deficiency or overexpression; yet, miR-139-/- CD8+ T cells are outcompeted by wild-type CD8+ T cells in a competition setting and demonstrate reduced responses to Listeria monocytogenes Using an in vitro model of T cell exhaustion, we confirmed that miR-139 expression similarly does not impact the development of T cell exhaustion. We conclude that despite significant downregulation of miR-139 following in vivo and in vitro activation, miR-139 expression is dispensable for influenza-specific CTL responses.
Collapse
Affiliation(s)
- Jennifer L Hope
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands; .,Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA.,Aging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Manzhi Zhao
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Christopher J Stairiker
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.,Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA
| | - Caoimhe H Kiernan
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Alison J Carey
- Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA.,Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
| | - Yvonne M Mueller
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.,Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA
| | - Marjan van Meurs
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Inge Brouwers-Haspels
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Dennis C Otero
- Aging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Eun-Ah Bae
- Aging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Hannah A Faso
- Aging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Alex Maas
- Department of Cell Biology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Hans de Looper
- Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Paolo M Fortina
- Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA; and
| | - Isidore Rigoutsos
- Computational Medicine Center, Thomas Jefferson University, Philadelphia, PA
| | - Linda M Bradley
- Aging, Cancer and Immuno-oncology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | - Stefan J Erkeland
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Peter D Katsikis
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands;
| |
Collapse
|
5
|
Li SZ, Ren KX, Zhao J, Wu S, Li J, Zang J, Fei Z, Zhao JL. miR-139/PDE2A-Notch1 feedback circuit represses stemness of gliomas by inhibiting Wnt/β-catenin signaling. Int J Biol Sci 2021; 17:3508-3521. [PMID: 34512162 PMCID: PMC8416740 DOI: 10.7150/ijbs.62858] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Accepted: 08/01/2021] [Indexed: 01/13/2023] Open
Abstract
Rationale: The malignant phenotypes of glioblastomas (GBMs) are primarily attributed to glioma stem cells (GSCs). Our previous study and other reports have suggested that both miR-139 and its host gene PDE2A are putative antitumor genes in various cancers. The aim of this study was to investigate the roles and mechanisms of miR-139/PDE2A in GSC modulation. Methods: Clinical samples were used to determine miR-139/PDE2A expression. Patient-derived glioma stem-like cells (PD-GSCs) were stimulated for immunofluorescent staining, sphere formation assays and orthotopic GBM xenograft models. Bioinformatic analysis and further in vitro experiments demonstrated the downstream molecular mechanisms of miR-139 and PDE2A. OX26/CTX-conjugated PEGylated liposome (OCP) was constructed to deliver miR-139 or PDE2A into glioma tissue specifically. Results: We demonstrated that miR-139 was concomitantly transcribed with its host gene PDE2A. Both PDE2A and miR-139 indicated better prognosis of gliomas and were inversely correlated with GSC stemness. PDE2A or miR-139 overexpression suppressed the stemness of PD-GSCs. FZD3 and β-catenin, which induced Wnt/β-catenin signaling activation, were identified as targets of miR-139 and mediated the effects of miR-139 on GSCs. Meanwhile, PDE2A suppressed Wnt/β-catenin signaling by inhibiting cAMP accumulation and GSK-3β phosphorylation, thereby modulating the self-renewal of PD-GSCs. Notably, Notch1, which is also a target of miR-139, suppressed PDE2A/miR-139 expression directly via downstream Hes1, indicating that miR-139 promoted its own expression by the miR-139-Notch1/Hes1 feedback circuit. Expectedly, targeted overexpression miR-139 or PDE2A in glioma with OCP system significantly repressed the stemness and decelerated glioma progression. Conclusions: Our findings elaborate on the inhibitory functions of PDE2A and miR-139 on GSC stemness and tumorigenesis, which may provide new prognostic markers and therapeutic targets for GBMs.
Collapse
Affiliation(s)
- San-Zhong Li
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Kai-Xi Ren
- Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Jing Zhao
- Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Shuang Wu
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Juan Li
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Jian Zang
- State Key Laboratory of Cancer Biology, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an 710032, China
| | - Zhou Fei
- Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China
| | - Jun-Long Zhao
- State Key Laboratory of Cancer Biology, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an 710032, China
| |
Collapse
|
6
|
Erkeland SJ, Stavast CJ, Schilperoord-Vermeulen J, Dal Collo G, Van de Werken HJG, Leon LG, Van Hoven-Beijen A, Van Zuijen I, Mueller YM, Bindels EM, De Ridder D, Kappers-Klunne MC, Van Lom K, Van der Velden VHJ, Langerak AW. The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia. Haematologica 2021; 107:143-153. [PMID: 33596640 PMCID: PMC8719092 DOI: 10.3324/haematol.2020.263756] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Indexed: 11/29/2022] Open
Abstract
T-cell prolymphocytic leukemia (T-PLL) is mostly characterized by aberrant expansion of small- to medium-sized prolymphocytes with a mature post-thymic phenotype, high aggressiveness of the disease and poor prognosis. However, T-PLL is more heterogeneous with a wide range of clinical, morphological, and molecular features, which occasionally impedes the diagnosis. We hypothesized that T-PLL consists of phenotypic and/or genotypic subgroups that may explain the heterogeneity of the disease. Multi-dimensional immuno-phenotyping and gene expression profiling did not reveal clear T-PLL subgroups, and no clear T-cell receptor a or b CDR3 skewing was observed between different T-PLL cases. We revealed that the expression of microRNA (miRNA) is aberrant and often heterogeneous in T-PLL. We identified 35 miRNA that were aberrantly expressed in T-PLL with miR-200c/141 as the most differentially expressed cluster. High miR- 200c/141 and miR-181a/181b expression was significantly correlated with increased white blood cell counts and poor survival. Furthermore, we found that overexpression of miR-200c/141 correlated with downregulation of their targets ZEB2 and TGFbR3 and aberrant TGFb1- induced phosphorylated SMAD2 (p-SMAD2) and p-SMAD3, indicating that the TGFb pathway is affected in T-PLL. Our results thus highlight the potential role for aberrantly expressed oncogenic miRNA in T-PLL and pave the way for new therapeutic targets in this disease.
Collapse
Affiliation(s)
- Stefan J Erkeland
- Department of Immunology, Erasmus University Medical Center, Rotterdam.
| | | | | | - Giada Dal Collo
- Department of Immunology, Erasmus University Medical Center, Rotterdam
| | - Harmen J G Van de Werken
- Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands; Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam
| | - Leticia G Leon
- Department of Immunology, Erasmus University Medical Center, Rotterdam
| | | | - Iris Van Zuijen
- Department of Immunology, Erasmus University Medical Center, Rotterdam
| | - Yvonne M Mueller
- Department of Immunology, Erasmus University Medical Center, Rotterdam
| | - Eric M Bindels
- Department of Hematology, Erasmus University Medical Center, Rotterdam
| | | | | | - Kirsten Van Lom
- Department of Hematology, Erasmus University Medical Center, Rotterdam
| | | | - Anton W Langerak
- Department of Immunology, Erasmus University Medical Center, Rotterdam.
| |
Collapse
|
7
|
Zhang W, Qu X, Zhu Z, Wang L, Qi Q, Zhou P, Wang X, Li W. Inhibition of miR-139-5p by topical JTXK gel promotes healing of Staphylococcus aureus-infected skin wounds. Cells Dev 2021; 166:203658. [PMID: 33994349 DOI: 10.1016/j.cdev.2021.203658] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 10/21/2020] [Accepted: 01/04/2021] [Indexed: 01/01/2023]
Abstract
BACKGROUND The inflammatory skin wound response is regulated by argonaute 2-bound microRNAs (Ago2-miRNAs) such as miR-139-5p, which inhibit transcription of their target mRNAs. Jiang Tang Xiao Ke (JTXK) is a traditional Chinese medicine that reduces miR-139-5p expression, suggesting that topical application of JTXK may have effects on wound healing. METHODS miR-139-/- mice and wild-type (WT) mice were employed to characterize the in vivo effects of miR-139-5p on sterile wound healing. Neutrophil migration and activation into the wound site were examined by live imaging analysis in lys-EGFP mice and myeloperoxidase/aminophenyl fluorescein assays, respectively. In silico and in vitro studies in differentiated HL60 cells were performed to identify miR-139-5p's downstream mediator(s). miR-139-/- neutrophil transplantation (with or without Eif4g2-knockdown rescue) or a topical JTXK gel preparation (with or without miR-139-5p mimic rescue) were employed to characterize the in vivo effects of miR-139-5p and JTXK, respectively, on Staphylococcus aureus (S. aureus)-infected wound healing. RESULTS miR-139-/- mice display impaired sterile wound healing but improved S. aureus-infected wound healing. Eif4g2, a protein that supports neutrophil proliferation and differentiation, was identified as a key downstream mediator of miR-139-5p. miR-139-/- mice show elevated neutrophilic activation and Eif4g2 upregulation. miR-139-/- neutrophils enhanced S. aureus-infected wound healing in an Eif4g2-dependent manner. Moreover, topical JTXK gel therapy also enhanced S. aureus-infected wound healing in a miR-139-5p-dependent manner. CONCLUSIONS miR-139-5p negatively regulates the neutrophilic response during S. aureus-infected wound healing, suggesting that JTXK or other miR-139-5p suppressants may be effective for treating infected skin wounds.
Collapse
Affiliation(s)
- Weitao Zhang
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China.
| | - Xu Qu
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| | - Zhang Zhu
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| | - Liwen Wang
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| | - Qian Qi
- Shaanxi University of Traditional Chinese Medicine, Xianyang, China
| | - Pengjun Zhou
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| | - Xiaoli Wang
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| | - Wenna Li
- Department of Dermatology, Affiliated Hospital of Shaanxi University of traditional Chinese Medicine, Xianyang, China
| |
Collapse
|
8
|
Xu J, Zhang Y, Liu C, Yan P, Yang Z. Roles of the miR-139-5p/CCT5 axis in hepatocellular carcinoma: a bioinformatic analysis. Int J Med Sci 2021; 18:3556-3564. [PMID: 34522182 PMCID: PMC8436101 DOI: 10.7150/ijms.57504] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Accepted: 08/06/2021] [Indexed: 02/05/2023] Open
Abstract
Background: MiRNAs are pivotal regulators involved in proliferation, apoptosis, invasion, metastasis, epithelial-mesenchymal transition (EMT), angiogenesis, drug resistance and autophagy in hepatocellular carcinoma (HCC). The aim of this study was to investigate the influence of miR-139-5p and its target genes on the outcomes of HCC. Methods: Survival analysis of miR-139-5p in HCC was conducted in Kaplan-Meier plotter. Target genes of miR-139-5p were identified in TargetScan, miRTarBase and starBase. Gene Expression Omnibus (GEO) series were used for the validation of miR-139-5p target genes. Cox proportional regression model was also established. Results: In Kaplan-Meier plotter, 163 HCC patients were included. MiR-139-5p downregulation was significantly associated with unfavorable overall survival (OS) and disease-free survival (DFS) in HCC patients (all P < 0.001). MiR-139-5p was significantly downregulated in HCC tumors and human hepatoma cell lines (all P < 0.05). As a target gene of miR-139-5p, CCT5 was overexpressed in HCC tumor tissues and peripheral blood mononuclear cells (all P < 0.05). A negative correlation between CCT5 and miR-139-5p was found in TCGA dataset. CCT5 overexpression was significantly associated with worse OS in HCC patients (P < 0.001), which was validated in the GSE14520 dataset (P = 0.017). CCT5 mRNA was significantly overexpressed in HCC patients with alpha-fetoprotein (AFP) > 300 ng/ml, BCLC staging B-C, TNM staging III and main tumor size > 5 cm (all P < 0.05). According to the Cox regression model of CCT5-interacting genes, HCC patients with high risk had poor OS compared to those with low risk in the TCGA dataset (P < 0.001), with the 1-year, 3-year, and 5-year ROC curves of an area under the curve (AUC) equal to 0.704, 0.662, and 0.631, respectively. Conclusions: MiR-139-5p suppresses HCC tumor aggression and conversely correlated with CCT5. The miR-139-5p/CCT5 axis might perform crucial functions in the development of HCC.
Collapse
Affiliation(s)
- Jingjing Xu
- Department of Pathology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
| | - Yuan Zhang
- Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
| | - Cheng Liu
- Department of Infectious Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
| | - Ping Yan
- Department of Infectious Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
- ✉ Corresponding authors: Zongguo Yang, MD, PhD, Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University. 2901 Caolang Road, Shanghai 201508, China. E-mail: ; Ping Yan, MD, Department of Infectious Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. E-mail:
| | - Zongguo Yang
- Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
- ✉ Corresponding authors: Zongguo Yang, MD, PhD, Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University. 2901 Caolang Road, Shanghai 201508, China. E-mail: ; Ping Yan, MD, Department of Infectious Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China. E-mail:
| |
Collapse
|
9
|
Khalili N, Nouri-Vaskeh M, Hasanpour Segherlou Z, Baghbanzadeh A, Halimi M, Rezaee H, Baradaran B. Diagnostic, prognostic, and therapeutic significance of miR-139-5p in cancers. Life Sci 2020; 256:117865. [PMID: 32502540 DOI: 10.1016/j.lfs.2020.117865] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 05/23/2020] [Accepted: 05/27/2020] [Indexed: 12/16/2022]
Abstract
miRNAs are a group of non-coding RNAs that have regulatory functions in post-transcriptional gene expression. These molecules play a fundamental role in cellular processes, for instance cell proliferation, apoptosis, migration, and invasion. Scientific investigations have previously established that miRNAs can either promote or suppress tumor development by mediating different signaling pathways. miR-139-5p, located on chromosome 11q13.4, has been examined extensively in cancers. Studies have demonstrated that miR-139-5p might be an attractive cancer biomarker. Herein, we will review how miR-139-5p acts in cancer diagnosis, prognosis, and therapy, as well as elucidating its major target genes and associated signaling pathways.
Collapse
Affiliation(s)
- Neda Khalili
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - Masoud Nouri-Vaskeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | | | - Amir Baghbanzadeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Monireh Halimi
- Department of Pathology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Haleh Rezaee
- Infectious Diseases and Tropical Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Clinical Pharmacy (Pharmacotherapy), Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Behzad Baradaran
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
10
|
Schneider E, Pochert N, Ruess C, MacPhee L, Escano L, Miller C, Krowiorz K, Delsing Malmberg E, Heravi-Moussavi A, Lorzadeh A, Ashouri A, Grasedieck S, Sperb N, Kumar Kopparapu P, Iben S, Staffas A, Xiang P, Rösler R, Kanduri M, Larsson E, Fogelstrand L, Döhner H, Döhner K, Wiese S, Hirst M, Keith Humphries R, Palmqvist L, Kuchenbauer F, Rouhi A. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells. Leukemia 2019; 34:1253-1265. [DOI: 10.1038/s41375-019-0651-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 10/09/2019] [Accepted: 11/13/2019] [Indexed: 12/31/2022]
|
11
|
Zhu M, Zhang W, Ma J, Dai Y, Zhang Q, Liu Q, Yang B, Li G. MicroRNA-139-5p regulates chronic inflammation by suppressing nuclear factor-κB activity to inhibit cell proliferation and invasion in colorectal cancer. Exp Ther Med 2019; 18:4049-4057. [PMID: 31616518 PMCID: PMC6781828 DOI: 10.3892/etm.2019.8032] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 08/22/2019] [Indexed: 12/12/2022] Open
Abstract
The inflammatory microenvironment, which mediates the initiation and malignant development of tumors, has been reported to be associated with microRNA (miRNA) dysregulation. In the present study, the expression of miR-139-5p was analyzed in colorectal cancer (CRC) cell lines SW480, HT29, HCT-8, LoVo and HCT116, aiming to investigate the function and mechanism of miR-139-5p in the regulation of the malignant phenotypes of CRC. miR-139-5p expression was found to be considerably downregulated in CRC cell lines compared with the human normal colon mucosal epithelial cell line NCM460. Subsequently, it was demonstrated that overexpression of miR-139-5p in colon cancer cell lines significantly suppressed the cell proliferation in vitro and in vivo. In addition, overexpression of miR-139-5p further inhibited the invasion ability of colon cancer cells in vitro, concomitantly with downregulation of key invasion-associated proteins, including matrix metalloproteinase 9 (MMP9) and MMP7. Furthermore, it was demonstrated that overexpression of miR-139-5p decreased the expression levels of inflammatory cytokines, including interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α), by suppressing nuclear factor (NF)-κB activity. Therefore, these findings collectively indicated that miR-139-5p regulated chronic inflammation by suppressing NF-κB activity in order to inhibit cell proliferation and invasion in CRC, thereby indicating a novel molecular mechanism in CRC therapy.
Collapse
Affiliation(s)
- Mingming Zhu
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Wen Zhang
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Jun Ma
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Youguo Dai
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Qi Zhang
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Qin Liu
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Burong Yang
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| | - Gang Li
- Department of Abdominal Tumor Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China
| |
Collapse
|
12
|
Wang H, He H, Yang C. miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2019; 47:3671-3676. [PMID: 31496296 DOI: 10.1080/21691401.2019.1596930] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Haiyan Wang
- Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| | - Heng He
- Department of Digestive Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| | - Chunyan Yang
- Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| |
Collapse
|
13
|
Zhang R, Tang P, Wang F, Xing Y, Jiang Z, Chen S, Meng X, Liu L, Cao W, Zhao H, Ma P, Chen Y, An C, Sun L. Tumor suppressor miR‐139‐5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway. J Cell Biochem 2018; 120:4423-4432. [PMID: 30367526 DOI: 10.1002/jcb.27728] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 08/29/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Ronghui Zhang
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Ping Tang
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Fang Wang
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Ying Xing
- Academy of Medical Sciences, Zhengzhou University Zhengzhou China
| | - Zhongxing Jiang
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Shaoqian Chen
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Xiaoli Meng
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Linxiang Liu
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Weijie Cao
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Huayan Zhao
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Ping Ma
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Yanli Chen
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Chao An
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| | - Ling Sun
- Department of Hematology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
| |
Collapse
|
14
|
Li J, Li Q, Lin L, Wang R, Chen L, Du W, Jiang C, Li R. Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT). BMC Neurol 2018; 18:133. [PMID: 30170559 PMCID: PMC6117922 DOI: 10.1186/s12883-018-1139-8] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 08/24/2018] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Glioma metastasis, invasion, epithelial-mesenchymal transition (EMT) and chemoresistance indicate poor prognosis. Accumulating evidence reveals that Notch1 is an important factor in tumour progression. However, the role of Notch1 in glioma EMT and associated microRNAs (miRNAs) with the Notch pathway remain controversial. METHODS Utilizing cBioPortal database to examine the gene signature of NOTCH1 (encoding Notch1), CDH2 (encoding N-cadherin) and SNAI1 (encoding Snail-1) in disease-free survival (DFS) and overall survival (OS). We analyzed the Notch1 expression from Oncomine. We used Western blot (WB), immunohistochemistry (IHC) and immunofluorescence to determine protein levels. Transcription was evaluated by quantitative real-time (qRT)-PCR. siRNA and lentivirus were used to knock down Notch1 and overexpress miR-139-5p, respectively. The migration and invasion of glioma cells were assessed by wound healing and transwell assays. Luciferase reporter assays were utilized to verify the relationship between Notch1 and miR-139-5p. A U87-implanted intracranial model was used to study the effect of miR-139-5p on tumour growth and Notch1 suppression efficacy or EMT reversion. RESULTS It revealed the association of NOTCH1, CDH2, SNAI1 genomic alterations with decreases in DFS and OS. Notch1 was upregulated in classical and proneural subtypes of GBM, and associated with tumour grade. Notch1 inhibition suppressed the biological behaviours of metastasis, invasion and EMT. Notch1 was identified as a novel direct target of miR-139-5p. MiR-139-5p overexpression partially phenocopied Notch1 siRNA, whereas the forced expression of Notch1 reversed the effects of miR-139-5p on the invasion of glioma. Moreover, intracranial tumourigenicity and EMT behaviours were reduced by the introduction of miR-139-5p and partially mediated by the decreased Notch1 expression. CONCLUSIONS miR-139-5p was identified as a tumour suppressor by negatively targeting Notch1, and this work suggests a possible molecular mechanism of the miR-139/Notch1/EMT axis for glioma treatment.
Collapse
Affiliation(s)
- Jianlong Li
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang, 150086, Harbin, People's Republic of China.,Department of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
| | - Qingbin Li
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang, 150086, Harbin, People's Republic of China.,Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin, 150086, China.,Chinese Glioma Cooperative Group (CGCG), Beijing, 100050, China
| | - Lin Lin
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang, 150086, Harbin, People's Republic of China.,Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin, 150086, China.,Chinese Glioma Cooperative Group (CGCG), Beijing, 100050, China
| | - Rui Wang
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
| | - Lingchao Chen
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Wenzhong Du
- Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150086, China
| | - Chuanlu Jiang
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang, 150086, Harbin, People's Republic of China. .,Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin, 150086, China. .,Chinese Glioma Cooperative Group (CGCG), Beijing, 100050, China.
| | - Ruiyan Li
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang, 150086, Harbin, People's Republic of China. .,Neuroscience Institute, Heilongjiang Academy of Medical Sciences, Harbin, 150086, China. .,Chinese Glioma Cooperative Group (CGCG), Beijing, 100050, China.
| |
Collapse
|
15
|
Ni H, Dai X, Leng X, Deng M, Qin Y, Ji Q, Xu C, Li J, Liu Y. Higher variety and quantity of microRNA-139-5p isoforms confer suppressive role in hepatocellular carcinoma. J Cell Biochem 2018; 119:6806-6813. [PMID: 29693285 DOI: 10.1002/jcb.26874] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Accepted: 03/21/2018] [Indexed: 01/14/2023]
Abstract
MiRNA isoforms (isomiRs) were defined as an addition or deletion of one or more nucleotides at the 5' or 3' ends or both. Different isomiRs of the same miRNA can target different genes, which have extended the regulatory scale medicated by miRNA. In this study, we systematically analyzed miRNA isoforms in hepatocellular carcinoma (HCC) based on The Cancer Genome Atlas (TCGA) data and further explore their role by in silico and in vitro studies. We found that higher variety and quantity of miR-139-5p isoforms negatively correlated with the malignancy of HCC. And patients with higher variety and quantity of iso-miR-139-5p exhibited favorable survival, independent of tumor stage. Interestingly, miR-139-5p -1|-1 showed increased complementary effect of its target IGF1R than the archetype of miR-139-5p, and could further inhibit cellular movement more vigorously than its archetype. In conclusion, not only miR-139-5p itself, but its isoforms' variety and quantity confer suppressive role in HCC.
Collapse
Affiliation(s)
- Hengli Ni
- Department of Pathology, Medical College of Soochow University, Suzhou, China
| | - Xiaoxiao Dai
- Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Xueqin Leng
- Department of Bioinformatics, Medical College of Soochow University, Soochow University, Suzhou, China
| | - Min Deng
- Department of Pathology, Medical College of Soochow University, Suzhou, China
| | - Yan Qin
- Department of Pathology, Medical College of Soochow University, Suzhou, China.,Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, China
| | - Qinghua Ji
- Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Chunfang Xu
- Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jianming Li
- Department of Pathology, Medical College of Soochow University, Suzhou, China
| | - Yao Liu
- Department of Pathology, Medical College of Soochow University, Suzhou, China.,Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China
| |
Collapse
|
16
|
Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F, Klusmann JH. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. J Clin Oncol 2018; 36:1007-1016. [DOI: 10.1200/jco.2017.75.2204] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Purpose Dysregulated microRNAs are implicated in the pathogenesis and aggressiveness of acute myeloid leukemia (AML). We describe the effect of the hematopoietic stem-cell self-renewal regulating miR-193b on progression and prognosis of AML. Methods We profiled miR-193b-5p/3p expression in cytogenetically and clinically characterized de novo pediatric AML (n = 161) via quantitative real-time polymerase chain reaction and validated our findings in an independent cohort of 187 adult patients. We investigated the tumor suppressive function of miR-193b in human AML blasts, patient-derived xenografts, and miR-193b knockout mice in vitro and in vivo. Results miR-193b exerted important, endogenous, tumor-suppressive functions on the hematopoietic system. miR-193b-3p was downregulated in several cytogenetically defined subgroups of pediatric and adult AML, and low expression served as an independent indicator for poor prognosis in pediatric AML (risk ratio ± standard error, −0.56 ± 0.23; P = .016). miR-193b-3p expression improved the prognostic value of the European LeukemiaNet risk-group stratification or a 17-gene leukemic stemness score. In knockout mice, loss of miR-193b cooperated with Hoxa9/Meis1 during leukemogenesis, whereas restoring miR-193b expression impaired leukemic engraftment. Similarly, expression of miR-193b in AML blasts from patients diminished leukemic growth in vitro and in mouse xenografts. Mechanistically, miR-193b induced apoptosis and a G1/S-phase block in various human AML subgroups by targeting multiple factors of the KIT-RAS-RAF-MEK-ERK (MAPK) signaling cascade and the downstream cell cycle regulator CCND1. Conclusion The tumor-suppressive function is independent of patient age or genetics; therefore, restoring miR-193b would assure high antileukemic efficacy by blocking the entire MAPK signaling cascade while preventing the emergence of resistance mechanisms.
Collapse
Affiliation(s)
- Raj Bhayadia
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Kathrin Krowiorz
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Nadine Haetscher
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Razan Jammal
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Stephan Emmrich
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Askar Obulkasim
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Jan Fiedler
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Adrian Schwarzer
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Arefeh Rouhi
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Michael Heuser
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Susanne Wingert
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Sabrina Bothur
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Konstanze Döhner
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Tobias Mätzig
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Michelle Ng
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Dirk Reinhardt
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Hartmut Döhner
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - C. Michel Zwaan
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Marry van den Heuvel Eibrink
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Dirk Heckl
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Maarten Fornerod
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Thomas Thum
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - R. Keith Humphries
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Michael A. Rieger
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Florian Kuchenbauer
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| | - Jan-Henning Klusmann
- Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and
| |
Collapse
|
17
|
Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P, De Luca L. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. Int J Mol Sci 2018; 19:ijms19020460. [PMID: 29401684 PMCID: PMC5855682 DOI: 10.3390/ijms19020460] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 01/12/2018] [Accepted: 01/12/2018] [Indexed: 02/07/2023] Open
Abstract
Acute myeloid leukemias (AML) are clonal disorders of hematopoietic progenitor cells which are characterized by relevant heterogeneity in terms of phenotypic, genotypic, and clinical features. Among the genetic aberrations that control disease development there are microRNAs (miRNAs). miRNAs are small non-coding RNAs that regulate, at post-transcriptional level, translation and stability of mRNAs. It is now established that deregulated miRNA expression is a prominent feature in AML. Functional studies have shown that miRNAs play an important role in AML pathogenesis and miRNA expression signatures are associated with chemotherapy response and clinical outcome. In this review we summarized miRNA signature in AML with different cytogenetic, molecular and clinical characteristics. Moreover, we reviewed the miRNA regulatory network in AML pathogenesis and we discussed the potential use of cellular and circulating miRNAs as biomarkers for diagnosis and prognosis and as therapeutic targets.
Collapse
MESH Headings
- Animals
- Antagomirs/genetics
- Antagomirs/metabolism
- Antagomirs/therapeutic use
- Biomarkers, Tumor/agonists
- Biomarkers, Tumor/antagonists & inhibitors
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Chromosome Aberrations
- Extracellular Vesicles/metabolism
- Extracellular Vesicles/pathology
- Gene Expression Regulation, Leukemic
- Humans
- Leukemia, Myeloid, Acute/diagnosis
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/metabolism
- Leukemia, Myeloid, Acute/therapy
- Mice
- MicroRNAs/agonists
- MicroRNAs/antagonists & inhibitors
- MicroRNAs/genetics
- MicroRNAs/metabolism
- Molecular Targeted Therapy
- Oligoribonucleotides/genetics
- Oligoribonucleotides/metabolism
- Oligoribonucleotides/therapeutic use
- Oncogene Proteins, Fusion/antagonists & inhibitors
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/metabolism
- Prognosis
- Signal Transduction
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Stefania Trino
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Italy.
| | - Daniela Lamorte
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Italy.
| | - Antonella Caivano
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Italy.
| | - Ilaria Laurenzana
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Italy.
| | - Daniela Tagliaferri
- Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', 83031 Ariano Irpino, Italy.
| | - Geppino Falco
- Biogem Scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', 83031 Ariano Irpino, Italy.
- Department of Biology, University of Naples Federico II, 80147 Naples, Italy.
| | - Luigi Del Vecchio
- CEINGE Biotecnologie Avanzate s.c.a r.l., 80147 Naples, Italy.
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, 80138 Naples, Italy.
| | - Pellegrino Musto
- Scientific Direction, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Potenza, Italy.
| | - Luciana De Luca
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028 Rionero in Vulture, Italy.
| |
Collapse
|
18
|
Nunez Lopez YO, Victoria B, Golusinski P, Golusinski W, Masternak MM. Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Rep Pract Oncol Radiother 2018; 23:6-20. [PMID: 29187807 PMCID: PMC5698002 DOI: 10.1016/j.rpor.2017.10.003] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 08/27/2017] [Accepted: 10/22/2017] [Indexed: 12/13/2022] Open
Abstract
AIM To characterize the miRNA expression profile in head and neck squamous cell carcinoma (HNSSC) accounting for a broad range of cancer subtypes and consequently identify an optimal miRNA signature with prognostic value. BACKGROUND HNSCC is consistently among the most common cancers worldwide. Its mortality rate is about 50% because of the characteristic aggressive behavior of these cancers and the prevalent late diagnosis. The heterogeneity of the disease has hampered the development of robust prognostic tools with broad clinical utility. MATERIALS AND METHODS The Cancer Genome Atlas HNSC dataset was used to analyze level 3 miRNA-Seq data from 497 HNSCC patients. Differential expression (DE) analysis was implemented using the limma package and multivariate linear model that adjusted for the confounding effects of age at diagnosis, gender, race, alcohol history, anatomic neoplasm subdivision, pathologic stage, T and N stages, and vital status. Random forest (RF) for survival analysis was implemented using the randomForestSRC package. RESULTS A characteristic DE miRNA signature of HNSCC, comprised of 11 upregulated (i.e., miR-196b-5p, miR-1269a, miR-196a-5p, miR-4652-3p, miR-210-3p, miR-1293, miR-615-3p, miR-503-5p, miR-455-3p, miR-205-5p, and miR-21-5p) and 9 downregulated (miR-376c-3p, miR-378c, miR-29c-3p, miR-101-3p, miR-195-5p, miR-299-5p, miR-139-5p, miR-6510-3p, miR-375) miRNAs was identified. An optimal RF survival model was built from seven variables including age at diagnosis, miR-378c, miR-6510-3p, stage N, pathologic stage, gender, and race (listed in order of variable importance). CONCLUSIONS The joint differential miRNA expression and survival analysis controlling for multiple confounding covariates implemented in this study allowed for the identification of a previously undetected prognostic miRNA signature characteristic of a broad range of HNSCC.
Collapse
Affiliation(s)
- Yury O. Nunez Lopez
- Translational Research Institute for Metabolism & Diabetes, Florida Hospital, 301 East Princeton St., Orlando, FL 32804, USA
| | - Berta Victoria
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Blvd., Orlando, FL 32827, USA
| | - Pawel Golusinski
- Department of Head and Neck Surgery, The Greater Poland Cancer Centre, 15 Garbary St., 61-866 Poznan, Poland
| | - Wojciech Golusinski
- Department of Head and Neck Surgery, The Greater Poland Cancer Centre, 15 Garbary St., 61-866 Poznan, Poland
| | - Michal M. Masternak
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Blvd., Orlando, FL 32827, USA
- Department of Head and Neck Surgery, The Greater Poland Cancer Centre, 15 Garbary St., 61-866 Poznan, Poland
| |
Collapse
|
19
|
ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma. Pathol Oncol Res 2017; 26:133-139. [DOI: 10.1007/s12253-017-0374-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 12/15/2017] [Indexed: 01/22/2023]
|
20
|
Qin L, Deng HY, Chen SJ, Wei W, Zhang YT. miR-139 acts as a tumor suppressor in T-cell acute lymphoblastic leukemia by targeting CX chemokine receptor 4. Am J Transl Res 2017; 9:4059-4070. [PMID: 28979681 PMCID: PMC5622250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Accepted: 09/01/2017] [Indexed: 06/07/2023]
Abstract
MicroRNAs (miRNAs) act as tumor regulators in T-cell acute lymphoblastic leukemia (T-ALL). However, the molecular mechanisms by which miRNA-139 (miR-139) regulates T-ALL remain unclear. In this study, we found that miR-139 was lowly expressed whereas C-X-C chemokine receptor type 4 (CXCR4) was highly expressed in T-ALL cell lines and patient samples. The T-ALL patients simultaneously with high levels of CXCR4 and low expression of miR-139 possessed poor prognosis. Moreover, the introduction of miR-139 inhibited T-ALL cell proliferation and invasion in vitro and suppressed tumor growth and lung metastasis in vivo. CXCR4 was identified as a direct target of miR-139. The suppressive effects of miR-139 were mimicked and counteracted by CXCR4 depletion and overexpression, respectively. Overall, the miR-139/CXCR4 axis plays an important role in T-ALL carcinogenesis.
Collapse
Affiliation(s)
- Ling Qin
- Department of Hematology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, Henan 471003, China
| | - Hui-Yang Deng
- Department of Hematology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, Henan 471003, China
| | - Sheng-Jiang Chen
- Department of Ultrasound, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, Henan 471003, China
| | - Wei Wei
- Department of Hematology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, Henan 471003, China
| | - Yi-Ting Zhang
- Department of Hematology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and TechnologyLuoyang, Henan 471003, China
| |
Collapse
|
21
|
Yu B, Dong H, Zang Y, Jiang S, Luan H, Zhang Y. MicroRNA-139-5p alleviates UVB-induced injuries by regulating TLR4 in si-IL-6-treated keratinocyte cells. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2017; 10:9293-9301. [PMID: 31966801 PMCID: PMC6965906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Accepted: 07/21/2017] [Indexed: 06/10/2023]
Abstract
Background: Lupus erythematosus (LE) is an autoimmune disease that is often exacerbated by ultraviolet B (UVB) irradiation. MicroRNAs (miRNAs) play vital roles in response to UVB damage to keratinocyte cells. Herein, our study aimed to explore the functions of miR-139-5p in UVB-induced injuries in keratinocyte cells. Methods: Human keratinocyte cell line HaCaT was per-treated with 20 ng/ml si-IL-6 and transfected with miR-139-5p mimic, pc-TLR4 and corresponding controls. These cells were underwent 30 mJ/cm2 UVB irradiation and incubated for 24 h. Thereafter, cell viability and apoptosis were detected by trypan blue staining and flow cytometry assays. Furthermore, the expression levels of miR-139-5p, TLR4, apoptosis-associated factors, Notch and PI3K/AKT pathways factors were examined by qRT-PCR and western blot. Results: Our results showed that UVB irradiation pronouncedly enhanced si-IL-6-induced cell injuries, as decreased cell viability and promoted apoptosis in HaCaT cells. In addition, miR-139-5p was up-regulated in UVB-exposed HaCaT cells and overexpression of miR-139-5p attenuated UVB-induced injuries in si-IL-6-treated HaCaT cells. Further study we found that overexpression of TLR4 significantly abolished the protective effects of miR-139-5p overexpression against UVB-induced injuries in si-IL-6-treated HaCaT cells. Besides, western blot results demonstrated that overexpression of miR-139-5p inactivated Notch and PI3K/AKT pathways by down-regulation of TLR4. Conclusions: These results indicated that miR-139-5p alleviated UVB-induced injuries by regulation of TLR4 in si-IL-6-treated HaCaT cells. The study might provide new therapeutic strategies for treatment of LE.
Collapse
Affiliation(s)
- Bo Yu
- Department of Dermatology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Hui Dong
- Department of Nephrology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Yunshu Zang
- Department of Dermatology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Shui Jiang
- Department of Dermatology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Hong Luan
- Department of Nephrology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Yue Zhang
- Department of Nephrology, The Affiliated Hospital of Qingdao UniversityQingdao, China
| |
Collapse
|
22
|
Hu G. MicroRNA-139: a potential diagnostic and therapeutic target for cancers. Hum Pathol 2017; 70:142-143. [PMID: 28823570 DOI: 10.1016/j.humpath.2017.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 06/21/2017] [Indexed: 11/17/2022]
Affiliation(s)
- Guxiu Hu
- Department of Pharmacy, Binhu Hospital of Hefei City, The First People's Hospital of Hefei, The Third Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China.
| |
Collapse
|
23
|
Wang K, Jin J, Ma T, Zhai H. MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9. J Cell Mol Med 2017; 21:3730-3740. [PMID: 28780773 PMCID: PMC5706525 DOI: 10.1111/jcmm.13282] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 05/23/2017] [Indexed: 12/27/2022] Open
Abstract
Our study sought to clarify the effects of microRNA-139-5p (miR-139-5p) in the tumorigenesis and progression of oral squamous cell carcinoma (OSCC) by regulating HOXA9. MiR-139-5p and HOXA9 expression in OSCC tissues, tumour adjacent tissues, OSCC cells and normal cells were tested by qRT-PCR. SAS and CAL-27 cell lines were selected in among four OSCC cell lines and then transfected with miR-139-5p mimics, pEGFP-HOXA9 and cotransfected with miR-139-5p mimics + pEGFP-HOXA9. We used MTT, colony formation, transwell and wound healing assays to analyse cell viability, proliferation, invasion and migration. The target relationship between miR-139-5p and HOXA9 was verified by luciferase reporter assay and Western blot, respectively. MiR-139-5p was down-regulated, whereas HOXA9 was up-regulated in OSCC tissues and cells. The proliferation, invasion and migration ability of SAS and CAL-27 cells in miR-139-5p mimics group were significantly weaker than those in the control group and the miR-NC group (P < 0.01). MiR-139-5p can negatively regulate HOXA9. The proliferation, invasion and migration of SAS and CAL-27 cells in the miR-139-5p mimics + pEGFP-HOXA9 group were not significantly different from those in the blank control and negative control groups (P > 0.05). Our results indicated that miR-139-5p could directly inhibit HOXA9, which might be a potential mechanism in inhibiting the proliferation, invasiveness and migration of OSCC cells.
Collapse
Affiliation(s)
- Kai Wang
- Department of Plastic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Jun Jin
- Department of Plastic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Tengxiao Ma
- Department of Plastic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Hongfeng Zhai
- Department of Plastic Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| |
Collapse
|
24
|
Yang L, Yin D, Wang Y, Cao L. Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139. Oncol Rep 2017; 38:2565-2571. [PMID: 28765917 DOI: 10.3892/or.2017.5869] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Accepted: 07/19/2017] [Indexed: 11/05/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is a highly malignant tumor and one of the most common causes for human cancer-related deaths. Fibroblast growth factor 18 (FGF18) is overexpressed in many types of cancer, and is associated with cell proliferation, invasion and angiogenesis. miR-139 has recently been reported as a tumor suppressor in various types of cancer and it can regulate many tumor-related genes, however its association with FGF18 expression in HCC has not been reported and thus remains unknown. In the present study, to explore the potential regulation mechanism of miR-139 with FGF18 in HCC, HCC tissues and cell lines were used. The results revealed that FGF18 was highly expressed in HCC tissues and cells, however miR-139 was lowly expressed. FGF18 was demonstrated to be a direct target of miR-139. Furthermore, the suppressive effect of miR-139 on FGF18 and in turn on proliferation, apoptosis, invasion, migration and tumor-induced angiogenesis of HCC cells was investigated. FGF18 was suggested as a prognostic biomarker and therapeutic target in HCC patients and miR-139 may be a promising strategy used in HCC treatment via the suppression of FGF18.
Collapse
Affiliation(s)
- Li Yang
- Department of Oncology, The First People's Hospital of Nantong, Nantong, Jiangsu 226001, P.R. China
| | - Dian Yin
- Department of Oncology, The First People's Hospital of Nantong, Nantong, Jiangsu 226001, P.R. China
| | - Yilang Wang
- Department of Oncology, The First People's Hospital of Nantong, Nantong, Jiangsu 226001, P.R. China
| | - Lili Cao
- Department of Oncology, The First People's Hospital of Nantong, Nantong, Jiangsu 226001, P.R. China
| |
Collapse
|